Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income. DOWNLOADS. Foreign Secretary statement on radical changes to Hong Kong’s electoral system. Non-GAAP income tax expense for the three and twelve months ended December 31, 2019 excludes a one-time tax benefit of $382.2 million related to the intra-entity asset transfer of intellectual property within our captive foreign partnership. The negative impact of foreign currency on total revenues year-over-year was 1 percent, or $45.1 million, inclusive of hedging activities. (1) Represents contingent milestone payments associated with acquisitions of legal entities accounted for as asset acquisitions. Alexion disclaims any obligation to update any of these forward-looking statements to reflect events or circumstances after the date hereof, except when a duty arises under law. Revenue of $494,600,000 rose by 120.51% from the same period last year, which beat the estimate of $443,100,000. Every day, we come to work with a singular purpose – to serve patients – and in 2019, we made significant strides in expanding the number of patients we are able to serve today and in the future. We have provided a few examples below that you can copy and paste to your site: Your data export is now complete. GAAP SG&A expense was $1,261.1 million, compared to $1,111.8 million in 2018. It is the leading industry news source for major companies across a number of industry verticals. Alexion Pharmaceuticals net income for the twelve months ending December 31, 2020 was $0.603B, a 74.9% decline year-over-year. Non-GAAP cost of sales was $110.8 million, compared to $93.0 million in the fourth quarter of 2018. Alexion Pharmaceutical’s total revenue, as in the figure below, has grown from US$ 4,131.2 million in 2018 to US$ 4,991.1 million in 2019, with a total growth of approximately 20.81%. Total revenues in the second quarter were $1,444.6 million , a 20 percent increase compared to the same period in 2019. Alexion Pharmaceuticals total assets for the quarter ending December 31, 2020 were $18.103B, a 3.18% increase year-over-year. GAAP cost of sales was $394.5 million, compared to $374.3 million in 2018. Terms of Use. This press release contains forward-looking statements, including statements related to: guidance regarding anticipated financial results for 2020 (and the assumptions related to such guidance); the strength of our business and continued growth; plans to expand the Company’s pipeline; Company’s goal of continuing to build on momentum as the year progresses; future plans for, and the timing for, the commencement of future clinical trials and the expected timing of the receipt of results of certain clinical trials and studies, including clinical programs for ULTOMIRIS in aHUS, NMOSD, HSCT-TMA, ALS, PNH, gMG, PPMS, a subcutaneous administration in PNH and aHUS, a higher concentration formulation of ULTOMIRIS, SOLIRIS in NMOSD and gMG, ALXN1840 in Wilson Disease, CAEL-101 in light chain (AL) amyloidosis, AG10 in ATTR-PN, danicopan in C3G and PNH patients with EVH, ACH-5228 for PNH and for ALXN1830 in WAIHA and gMG; potential benefits of current products and products under development and in clinical trials; plans for development programs with third parties including, Eidos, Affibody, Dicerna, Zealand, and Complement Pharma; the potential to treat a broad range of complement mediated diseases with the products to be developed with Zealand and Dicerna and the potential advantages of novel peptide therapies; the potential for the anti-eotaxin-1 antibody from Immune Pharma to treat inflammatory diseases; the potential for CP010 to treat multiple neurological disorders; and Alexion’s future clinical, regulatory, and commercial plans for ULTOMIRIS and other products and product candidates. News, Covid and the Closing of America’s Schools, Amazon set for first fulfilment centre in Amarillo, TX, Mar 3, 2021 Ahold Delhaize publishes 2020 Annual Re…, London police criticised for detaining demonstrators at Sarah Everard vigil, WHO reports over 492,000 new daily cases of COVID-19, Lineage Logistics raises new equity to fund investment in capacity and technology, Football Index business suspended as gambling operator enters administration, Travel Alert: Winter Storm To Hit Colorado Stations, Bangladesh may delay edn institutions reopening amid virus surge, Response to media coverage on National Audit Office report on the Culture Recovery Fund, SPOTLIGHT: Crówn, the ‘Lagbaja-endorsed’ Afrobeat gem hurtling to stardom – TheCable Lifestyle, Pfizer Polska boss upbeat on this year’s vaccination prospects. Total assets can be defined as the sum of all assets on a company's balance sheet. Non-GAAP diluted EPS for the full year of 2019 was $10.53, a 33 percent increase versus the prior year. During the three and twelve months ended December 31, 2018, we recognized unrealized gains of $57.7 million and $43.1 million, respectively, in investment income to adjust our strategic equity investments to fair value. (1) In February 2016, the Financial Accounting Standards Board issued a new standard that requires lessees to recognize leases on-balance sheet. Alexion Pharmaceuticals Inc (NASDAQ:ALXN) Q4 2019 Earnings Conference Call January 30, 2020 7:30 AM ET. Backlinks from other websites are the lifeblood of our site and a primary source of new traffic. Alexion is a global biopharmaceutical company focused on developing life-changing therapies for people living with rare … eBooksU.S. Upon adoption of the new lease standard, we derecognized $472.8 million of property, plant and equipment and other assets and $372.2 million of facility lease obligations associated with previously existing build-to-suit arrangements which resulted in a decrease of $90.3 million to retained earnings, net of tax. Corporate Participants: Morgan Sanford — Director of Investor Relations. You also have the option to opt-out of these cookies. GAAP R&D expense was $886.0 million, compared to $730.4 million in 2018. Susan Altschuller - Vice President of Investor Relations. This category only includes cookies that ensures basic functionalities and security features of the website. The non-GAAP results, determined in accordance with our internal policies, exclude the impact of the following GAAP items (see reconciliation tables below for additional information): share-based compensation expense, fair value adjustment of inventory acquired, amortization of purchased intangible assets, changes in fair value of contingent consideration, restructuring and related expenses, upfront payments related to licenses and other strategic agreements, acquired in-process research and development, impairment of purchased intangible assets, gains and losses related to strategic equity investments, litigation charges, gain or loss on sale of a business or asset, gain or loss related to purchase options, contingent milestone payments associated with acquisitions of legal entities accounted for as asset acquisitions, acquisition-related costs and certain adjustments to income tax expense. Alexion Pharmaceuticals annual/quarterly revenue history and growth rate from 2006 to 2020. (7) Alexion’s non-GAAP income tax expense for the three and twelve months ended December 31, 2019 and 2018 excludes the tax effect of pre-tax adjustments to GAAP profit. Non-GAAP R&D expense was $720.9 million, compared to $646.2 million in 2018. We also use third-party cookies that help us analyze and understand how you use this website. 2020 financial guidance assumes a GAAP effective tax rate of 15.5 to 16.5 percent and a non-GAAP effective tax rate of 16.0 to 17.0 percent for the year. Alexion also uses these non-GAAP financial measures to establish budgets, set operational goals and to evaluate the performance of the business. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. Looking back at the last five years, Alexion Pharmaceuticals's revenue peaked in March 2020 at $5.295 billion. Total revenues in the third quarter were $1,263.1 million , a 23 percent increase compared to the same period in 2018. If you use our chart images on your site or blog, we ask that you provide attribution via a "dofollow" link back to this page. 2019 annual report Lead(ing) We are redefining the standard of care for people living with PNH and aHUS with ULTOMIRIS, which has a unique value proposition that is supported by patient preference of going to the hospital every two months, for adults, instead of every two weeks. Craft can deliver 250+ data points of financial, operating, and human capital indicators on companies via API. Today is #EmployeeAppreciationDay and we are deeply grateful for the dedication and resilience of our 3,000+ employees worldwide. Alexion@AlexionPharma2 days ago. Alexion Pharmaceuticals annual net income for 2019 was $2.404B, a 2998.32% increase from 2018. In connection with the agreement of the final working capital adjustment for the Syntimmune acquisition, we recognized a benefit of $4.1 million associated with previously acquired in-process research and development in the second quarter of 2019. The 2020 GAAP and non-GAAP tax rates do not benefit from one-time events that benefited the tax rates in 2019. Tax Checklist for Full-Time Business Owners [Free Download]U.S. Tax Checklist for Full-Time Business Owners [Free Download]Read More, Statement on entry into force of the International Agreement on Taxation and the Protection of Financial Interests between the UK and Spain regarding Gibraltar, Dr. Fauci Chooses Between Pfizer, Moderna and Johnson & Johnson Vaccines on ‘Colbert’, ‘They left us out to dry’: Wildland firefighter says he was ‘blacklisted’ for speaking against lack of Covid safety, DHL Express opens international hub at Malpensa Airport, Georgia receives Oxford/AstraZeneca COVID-19 vaccine, Alarm as single-day Covid tally hits 2,701, 85% of consumer business leaders prioritising profitable and sustainable growth in 2021, despite greater cost reductions and smaller profits, White & Case Advises Lenders on €160 Million Financing to Clessidra SGR | White & Case LLP, CORRECTED-EXCLUSIVE-China’s JD.com in talks to buy stake worth $1.5 bln in brokerage – sources, Royal Mail posties pick-up over one million parcels since launch of Parcel Collect, Florida Gov. In addition, the company is developing several mid-to-late-stage therapies, including a copper-binding agent for Wilson disease, an anti-neonatal Fc receptor (FcRn) antibody for rare Immunoglobulin G (IgG)-mediated diseases and an oral Factor D inhibitor as well as several early-stage therapies, including one for light chain (AL) amyloidosis, a second anti-FcRn therapy, a second oral Factor D inhibitor and a third complement inhibitor. The company has since been renamed Alexion Antibody Technologies Inc. Alexion (ALXN) delivered earnings and revenue surprises of 12.05% and 1.87%, respectively, for the quarter ended September 2019. TABLE 3: RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL GUIDANCE, (in millions, except per share amounts and percentages), Gains and losses related to strategic equity investments, Diluted non-GAAP earnings per common share, Operating expense and margin (% total revenues), Non-GAAP research and development expense, GAAP selling, general and administrative expense, Non-GAAP selling, general and administrative expense, Income tax expense (% of income before income taxes), Tax effect of pre-tax adjustments to GAAP net income. Net product sales $ 1,588.3 $ 1,263.1 $ 4,477.4 $ 3,605.8 Other revenue 0.4 If you use our datasets on your site or blog, we ask that you provide attribution via a "dofollow" link back to this page. Ludwig Hantson — Chief Executive Officer. We received $114.7 million in net proceeds, resulting in a realized gain of $77.2 million on our initial investment. It is mandatory to procure user consent prior to running these cookies on your website. Please check your download folder. Prior to that, the total EPS $6.76 to $7.96 GAAP, $9.25 to $9.45 non-GAAP. Non-GAAP R&D expense was $226.7 million, compared to $164.0 million in the fourth quarter of 2018. Where are Alexion Pharmaceuticals … Do the numbers hold clues to what lies ahead for the stock? John Orloff — Executive Vice President and Head of Research & Development 2019 highlights We began 2019 with a solid foundation of science, innovation and a willingness to push the boundaries of medicine in order to better serve people living with rare diseases. GAAP SG&A expense was $381.0 million, compared to $318.7 million in the fourth quarter of 2018. STRENSIQ net product sales were $166.8 million, compared to $126.1 million in the fourth quarter of 2018, representing a 32 percent increase. 2019 ANNUAL REPORT. Legal. Boston biotech Alexion Pharmaceuticals Inc.’s fight to keep a hold on its flagship drug Soliris encountered a new challenge Friday, causing a stock … The acquisitions were both accounted for as asset acquisitions, as substantially all of the fair value of the gross assets acquired were concentrated in a single asset. Alexion Pharmaceuticals headquarters is located at 121 Seaport Blvd, Boston. Alexion Pharmaceuticals, Inc (NASDAQ: ALXN) | 2019 Annual Report. Top 1000 Companies Ranked by Revenue – in Multiple Sectors & Countries. DOWNLOADS. As a percent of revenue: R&D 19% to 20% GAAP or 16% to 17% non GAAP. On a GAAP basis, diluted EPS for the full year of 2019 was $10.70, inclusive of one-time tax benefits related to intra-entity asset transfers of intellectual property, compared to $0.35 in the prior year, inclusive of $1,183.0 million of expense related to the value of the in-process research and development assets acquired in 2018. Ron DeSantis vows state will not lock down despite Biden’s warning in address. Where is Alexion Pharmaceuticals headquarters? Our objectives reflected an ambition to expand our leadership in rare disease through new and existing indications while creating meaningful value for all our stakeholders. These cookies do not store any personal information. Alexion Pharmaceuticals Revenue 2006-2020 | ALXN, Alexion Pharmaceuticals revenue for the quarter ending December 31, 2020 was, Alexion Pharmaceuticals revenue for the twelve months ending December 31, 2020 was, Alexion Pharmaceuticals annual revenue for 2020 was, Alexion Pharmaceuticals annual revenue for 2019 was, Alexion Pharmaceuticals annual revenue for 2018 was. Alexion is the global leader in complement inhibition and has developed and commercializes the first and only approved complement inhibitor to treat patients with paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), and anti-acetylcholine receptor (AchR) antibody-positive generalized myasthenia gravis (gMG). The company revised up its full-year revenue guidance and the stock gained sharply during the premarket session. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sales of goods or services. GAAP income tax benefit was $287.0 million, inclusive of one-time tax benefits related to intra-entity asset transfers of intellectual property in the fourth quarter of 2019, compared to expense of $12.1 million in the fourth quarter of 2018. News, IR35 private sector changes coming in April 2021 – Which? Forward-looking statements are subject to factors that may cause Alexion’s results and plans to differ materially from those forward-looking statements, including for example: our dependence on sales from our principal product (SOLIRIS); our ability to facilitate the timely conversion of from SOLIRIS to ULTOMIRIS; payer, physician and patient acceptance of ULTOMIRIS as an alternative to SOLIRIS; appropriate pricing for ULTOMIRIS; future competition from biosimilars and novel products; decisions of regulatory authorities regarding the adequacy of our research, marketing approval or material limitations on the marketing of our products; delays or failure of product candidates to obtain regulatory approval; delays or the inability to launch product candidates due to regulatory restrictions, anticipated expense or other matters; interruptions or failures in the manufacture and supply of our products and our product candidates; failure to satisfactorily address matters raised by the FDA and other regulatory agencies; results in early stage clinical trials may not be indicative of full results or results from later stage or larger clinical trials (or broader patient populations) and do not ensure regulatory approval; the possibility that results of clinical trials are not predictive of safety and efficacy and potency of our products (or we fail to adequately operate or manage our clinical trials) which could cause us to halt trials, delay or prevent us from making regulatory approval filings or result in denial of approval of our product candidates; unexpected delays in clinical trials; unexpected concerns that may arise from additional data or analysis obtained during clinical trials; future product improvements may not be realized due to expense or feasibility or other factors; uncertainty of long-term success in developing, licensing or acquiring other product candidates or additional indications for existing products; inability to complete planned acquisitions due to failure of regulatory approval or material changes in target or otherwise; inability to complete acquisitions and investments due to increased competition for technology; the possibility that current rates of adoption of our products are not sustained; the adequacy of our pharmacovigilance and drug safety reporting processes; failure to protect and enforce our data, intellectual property and proprietary rights and the risks and uncertainties relating to intellectual property claims, lawsuits and challenges against us (including intellectual property lawsuits relating to ULTOMIRIS brought by third parties against Alexion and inter partes review petitions submitted by third parties); the risk that third party payors (including governmental agencies) will not reimburse or continue to reimburse for the use of our products at acceptable rates or at all; failure to realize the benefits and potential of investments, collaborations, licenses and acquisitions; the possibility that expected tax benefits will not be realized; assessment of impact of recent accounting pronouncements; potential declines in sovereign credit ratings or sovereign defaults in countries where we sell our products; delay of collection or reduction in reimbursement due to adverse economic conditions or changes in government and private insurer regulations and approaches to reimbursement; uncertainties surrounding legal proceedings, company investigations and government investigations, including investigations of Alexion by the U.S. Securities and Exchange Commission (SEC) and U.S. Department of Justice; the risk that estimates regarding the number of patients with PNH, aHUS, gMG, NMOSD, HPP and LAL-D and other future indications we are pursuing are inaccurate; the risks of changing foreign exchange rates; risks relating to the potential effects of the Company’s restructuring; risks related to the acquisition of companies and co-development and collaboration efforts; and a variety of other risks set forth from time to time in Alexion’s filings with the SEC, including but not limited to the risks discussed in Alexion’s Quarterly Report on Form 10-Q for the period ended September 30, 2019 and in our other filings with the SEC. TABLE 1: CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS, Acquired in-process research and development, Amortization of purchased intangible assets, Change in fair value of contingent consideration, Shares used in computing earnings (loss) per common share, TABLE 2: RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL RESULTS, Upfront payments related to licenses and other strategic agreements (2). At the time Proliferon's annual revenue was about $2.5 million and its assets were valued at $2.1 million. Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) Q2 2019 Earnings Conference Call July 24, 2019 8:00 AM ET Company Participants. These cookies will be stored in your browser only with your consent. Our key achievements include establishing ULTOMIRIS as the market leader in PNH within the first year of launch, expanding our C5 portfolio to make neurology our largest franchise in the U.S., and further diversifying our pipeline with seven business development deals adding five clinical-stage assets to our portfolio,” said Ludwig Hantson, Ph.D., Chief Executive Officer of Alexion. Alexion is a global biopharmaceutical company focused on serving patients and families affected by rare diseases through the discovery, development and commercialization of life-changing medicines. “I am confident we are well positioned for the future and will build on our momentum in 2020, with a continued focus on delivering long-term shareholder value by advancing our mission of developing and delivering transformative medicines for people with rare diseases.”. Please refer to the attached Reconciliations of GAAP to non-GAAP Financial Results and GAAP to non-GAAP 2020 Financial Guidance for explanations of the amounts adjusted to arrive at non-GAAP net income and non-GAAP earnings per share amounts for the three and twelve month periods ended December 31, 2019 and 2018 and projected twelve months ending December 31, 2020. Submit a press release. Non-GAAP income tax expense was $85.8 million, compared to $88.5 million in the fourth quarter of 2018. The negative impact of foreign currency on total revenues year-over-year was 1 percent, or $45.1 million, inclusive of hedging activities. Each plays a critical role in … Alexion Pharmaceuticals EBITDA for the twelve months ending December 31, 2020 was $3.015B, a 20.74% increase year-over-year. This press release and further information about Alexion can be found at: www.alexion.com. Alexion Pharmaceuticals Inc (NASDAQ: ALXN) Q4 2019 Earnings Conference Call January 30, 2020. These non-GAAP financial measures are not intended to be considered in isolation or as a substitute for, or superior to, the financial measures prepared and presented in accordance with GAAP, and should be reviewed in conjunction with the relevant GAAP financial measures. Selling, general and administrative expense: Acquired in-process research and development (3), Change in fair value of contingent consideration (4), (Gains) and losses related to strategic equity investments (5), GAAP earnings (loss) per common share – diluted, Non-GAAP earnings per common share – diluted, Shares used in computing diluted earnings (loss) per common share (GAAP), Shares used in computing diluted earnings per common share (non-GAAP). During the twelve months ended December 31, 2019, we recorded expense of $103.4 million in connection with upfront payments on strategic agreements that we entered into with Stealth, Immune Pharma, Eidos Therapeutics, Inc., Affibody AB and Zealand Pharma A/S. Alexion Pharmaceuticals (Nasdaq: ALXN) reported strong results for the second quarter of 2019. Company News HQ is a global business news portal. Alexion Pharmaceuticals Inc (NASDAQ:ALXN) Q3 2019 Results Earnings Conference Call October 23, 2019 08:00 A.M. On a GAAP basis, diluted EPS in the quarter was $4.00, inclusive of one-time tax benefits related to intra-entity asset transfers of intellectual property, compared to $(0.20) in the prior year, inclusive of $379.3 million of expense related to the value of the in-process research and development asset acquired in connection with our acquisition of Syntimmune in the fourth quarter of 2018. (4) Changes in the fair value of contingent consideration expense for the three and twelve months ended December 31, 2019 as well as the three months ended December 31, 2018 include the impact of changes in the expected timing of achieving contingent milestones, in addition to the interest component related to the passage of time. Headquartered in Boston, Massachusetts, Alexion has offices around the globe and serves patients in more than 50 countries. 2019 ANNUAL REPORT. A replay of the call will be available for a limited period following the call. ULTOMIRIS net product sales were $170.2 million in the fourth quarter of 2019. (5) On December 9, 2019, we sold our Moderna Therapeutics Inc. strategic equity investment. Find detailed stats on Alexion Pharmaceuticals revenue on Craft. The value of the acquired in-process research and development assets was expensed during the quarters the acquisitions were completed due to the stage of development of the assets. Aradhana Sarin — Executive Vice President and Chief Financial Officer. Conference Highlights: Non-GAAP income tax expense for the three and twelve months ended December 31, 2018 excludes adjustments to provisional estimates of the impact of Tax Cuts and Jobs Act we recorded in fourth quarter 2017. For a detailed definition, formula and example for. Total revenues in the third quarter were $1,588.7 million, a 26 percent increase compared to the same period in 2019. Necessary cookies are absolutely essential for the website to function properly. To participate in the call, dial 866-762-3111 (USA) or 210-874-7712 (International), conference ID 3571658 shortly before 7:30 a.m. Eastern Time. Alexion Pharmaceuticals 2019 annual EBITDA was $2.497B, a … In addition, we capitalized $326.1 million and $255.3 million of right of use assets and lease liabilities, respectively, within our condensed consolidated balance sheet upon adoption. GAAP cost of sales was $114.3 million, compared to $96.8 million in the fourth quarter of 2018. Want to share your news with your industry? In conjunction with this amendment, we recognized a gain of $32.0 million in other income and (expense), which reflects an increase in the fair value of the option, less incremental upfront funding and the change in the fair value of contingent payments which we also modified as part of the amendment. ALEXION PHARMACEUTICALS, INC. TABLE 1: CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (in millions, except per share amounts) (unaudited) Three months ended March 31, 2020 2019. Please check your download folder. Non-GAAP cost of sales was $380.3 million, compared to $352.5 million in 2018. Privacy Policy. Net product sales were $4,990.0 million, compared to $4,130.1 million in 2018. GAAP R&D expense was $269.6 million, compared to $205.6 million in the fourth quarter of 2018. The results also topped the Street view. TABLE 5: CONDENSED CONSOLIDATED BALANCE SHEETS, Prepaid expenses and other current assets (1), Current portion of contingent consideration, Total liabilities and stockholders’ equity. Total revenues for the full year of 2019 were $4,991.1 million, a 21 percent increase compared to 2018. Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. Alexion will host a conference call/audio webcast to discuss the fourth quarter and full-year 2019 results today at 7:30 a.m. Eastern Time. SG&A 23% to 24% GAAP or 20% to 21% non-GAAP. GAAP diluted EPS was $4.00, inclusive of one-time tax benefits related to intra-entity asset transfers of intellectual property in the fourth quarter of 2019, compared to $(0.20) in the fourth quarter of 2018, inclusive of $379.3 million of expense related to the value of the in-process research and development asset acquired in connection with our acquisition of Syntimmune. This website uses cookies to improve your experience while you navigate through the website. BOSTON–(BUSINESS WIRE)–Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced financial results for the fourth quarter and full year of 2019. ALEXION PHARMACEUTICALS, INC. TABLE 1: CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (in millions, except per share amounts) (unaudited) Three months ended Nine months ended September 30, September 30, 2020 2019 2020 2019. ; Alexion Pharmaceuticals total assets for 2020 were $18.103B, a 3.18% increase from 2019. The audio webcast can be accessed on the Investor page of Alexion’s website at: http://ir.alexion.com. A MESSAGE FROM OUR CEO. Morgan Sanford - Director of Investor Relations. (1) The following table summarizes the total restructuring and related expenses recorded by type of activity and the classification within the Reconciliation of GAAP to non-GAAP Financial Results: (2) During the three months ended December 31, 2019, we recorded expense of $27.1 million in connection with upfront payments on strategic agreements that we entered into with Stealth BioTherapeutics Corp. (Stealth) and Immune Pharmaceuticals (Immune Pharma).
Dsds Jury 2022, Lansinoh Hpa Lanolin Dm, B1 Stau Aktuell, Tony Marshall Gestorben 2020, Schaffrath Küchen Bewertung, Pella In Decapolis,
Neue Kommentare